You are focusing on the wrong person - you should be evaluating Jens Kiein.
He is a seasoned executive in terms of both investment financing and management of a chemical company, Suggest you reread the last paragraph of the press release with the comments from Amsilks Chairman of the board.
Amsilk is light years ahead of KBLB from a business perspective - they are producing their own finished products (meaning they are vertically integrated - which significantly improves profit margins) / well financed / clear product development objective - timeline / they have an actual company with staff for R&D / sales / processing (KBLB has a part time secretary - YEAH)
Klein is the real deal. Amsilk is already selling one of their products (for cosmetics), and are on the door step with at least two others for later this year. Low volume, but very high margin products.
Market Data 
Markets 
AI
